Spyre Therapeutics, Inc. (SYRE) — Revenue
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $0 | — |
| 2024 | $0 | -100.0% |
| 2023 | $886.0K | -62.0% |
| 2022 | $2.33M | -87.6% |
| 2021 | $18.74M | — |
| 2020 | $0 | — |
| 2019 | $0 | -100.0% |
| 2018 | $3.89M | -25.3% |
| 2017 | $5.21M | +12.5% |
| 2016 | $4.63M | — |
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $0 | — |
| 2024 | $0 | -100.0% |
| 2023 | $886.0K | -62.0% |
| 2022 | $2.33M | -87.6% |
| 2021 | $18.74M | — |
| 2020 | $0 | — |
| 2019 | $0 | -100.0% |
| 2018 | $3.89M | -25.3% |
| 2017 | $5.21M | +12.5% |
| 2016 | $4.63M | — |